Type 1 Diabetes

Lifelong condition may join list of various medical ailments for which type 1 patients are at an increased risk… A population-based cohort study published using data from The Health Improvement Network (THIN) was evaluated comparing records from 303,394 type 1 diabetes patients aged 0-89 years old with 303,872 random controls …

When mice are given IL-35, type 1 diabetes is either reversed or completely cured as blood glucose returned to normal… Type 1 diabetes is considered an autoimmune disease in which the immune system attacks insulin-producing beta pancreatic cells. To better understand how to treat type 1 diabetes, Swedish researchers injected …

The risk of eating disorders and disordered eating behavior is higher for female adolescents with type 1 diabetes than their non-diabetic counterparts, and remains higher well into adulthood… A recently study followed 126 adolescent girls with type 1 diabetes treated at the diabetes center of the Hospital for Sick Children …

A female chef, 28 years of age with type 1 diabetes over 18 years, reported extreme glucose excursions. She had pretty good control up until she took on this profession….

Dr. Paolo Fiorina explains how, after 30 years of research into the potential of stem cell therapy and immunotherapy for curing type 1 diabetes, new developments in these fields are offering genuine hope for the first time. In a recent study with about 60 type 1 patients, significant progress was …

JDRF-funded studies on development of artificial pancreas, encapsulated islet cell therapies, and kidney preservation presented at 2015 ADA Scientific Sessions.

SGLT-2 inhibitors are a new class of drug for the treatment of type 2 diabetes, but they are also being used off label in patients with type 1 diabetes.

A clinical trial to investigate whether repeated injections of the tuberculosis vaccine bacille Calmette-Guérin holds promise… The researchers announced the start of their phase 2 trial at the American Diabetes Association (ADA) 75th Scientific Sessions in Boston. Study author Denise Faustman, MD, director of the immunobiology laboratory at Massachusetts General …

Combination of insulin, a GLP-1 receptor agonist and an SGLT-2 inhibitor effective, includes DKA risk.

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, is a promising option as adjunct therapy for type 1 diabetes patients… In a randomized double blind phase 2 study, 33 type 1 diabetic patients were treated with either sotagliflozin or placebo. Researchers assessed safety, glycemic control, bolus insulin dose reduction which was …